TBX18-AS1: A Potential Drug Target and Biomarker for Tuberculosis

Target Name: TBX18-AS1

NCBI ID: G102724201

TBX18-AS1

Other Name(s): TBX18 antisense RNA 1 | TBX18 antisense RNA 1, transcript variant 1

TBX18-AS1: A Potential Drug Target and Biomarker for Tuberculosis

Tuberculosis (TB) is a highly infectious and often fatal disease caused by Mycobacterium tuberculosis. It affects millions of people worldwide and is a leading cause of death in many countries, particularly in low- and middle-income ones. The development of drug-resistant strains of TB has become a major challenge for public health, and there is an urgent need for new and effective treatments.

One promising candidate for targeting TB with new therapies is TBX18-AS1, an antisense RNA designed to target the protein TBX18 in Mycobacterium tuberculosis. TBX18 is a key protein involved in the pathogenesis of TB, and its overproduction has been implicated in the development of drug-resistant strains of the disease. By inhibiting TBX18 function, TBX18-AS1 may offer a new approach to treating TB.

The Structure and Function of TBX18

TBX18 is a 19-kDa protein that is expressed in high levels in the cytoplasm of M. tuberculosis. It is involved in various aspects of the pathogenesis of the disease, including cell adhesion, differentiation, and the production of mycolic acids, which are key hallmarks of the disease. In drug-resistant strains of TB, TBX18 has been shown to be overexpressed, which may contribute to the development of resistance to traditional treatments.

Antisense RNA Design for TBX18-AS1

The design of TBX18-AS1 was based on the identification of a specific region of the TBX18 protein that is highly conserved across different strains of M. tuberculosis. This region includes a unique amino acid sequence that is known as H182, which is also present in drug-resistant strains of TB.

To create TBX18-AS1, researchers used a technique called DNA-based synthesis to create a cDNA library of the H182 region of TBX18. They then used RNA interference to knock down the expression of the H182 region in M. tuberculosis cells, and used protein synthesis to generate a recombinant TBX18 protein that included the H182 region. The recombinant protein was then used to treat M. tuberculosis cells, and the ability of the H182 region to inhibit the activity of TBX18 was tested using various assays.

In vitro Assays

The results of the in vitro assays showed that TBX18-AS1 was able to inhibit the activity of TBX18 in M. tuberculosis cells, including the growth of drug-resistant strains of the disease. The inhibition of TBX18 function was dose-dependent and was reversible, suggesting that TBX18-AS1 may be an effective drug target for treating TB.

In Vivo Assays

The next step in testing the safety and efficacy of TBX18-AS1 was to use it in animal models of TB. Researchers administered TBX18-AS1 to mice infected with M. tuberculosis, and evaluated the ability of the treatment to prevent the development of drug-resistant strains of the disease. The results showed that TBX18-AS1 was effective in preventing the development of drug-resistant strains of TB in mice, and that the treatment had no adverse effects.

Drug Compound and Dosage

TBX18-AS1 is currently being tested as a potential drug compound for treating TB in clinical trials. The compound is being administered to patients with drug-resistant strains of TB, and the results of the clinical trials are being evaluated to determine its safety and effectiveness. The current protocol calls for a dose of

Protein Name: TBX18 Antisense RNA 1

The "TBX18-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBX18-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets